(Q34926739)

5 August 2017

1 reference

title

Anti-CD20-based therapy of B cell lymphoma: state of the art. (English)

1 reference

5 August 2017

Kosmas C

1

1 reference

5 August 2017

Stamatopoulos K

2

1 reference

5 August 2017

Stavroyianni N

3

1 reference

5 August 2017

Tsavaris N

4

1 reference

5 August 2017

Papadaki T

5

1 reference

5 August 2017

publication date

1 October 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

16

1 reference

5 August 2017

issue

10

1 reference

5 August 2017

page(s)

2004-2015

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402639

5 August 2017

exact match

0 references

cites work

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Antibodies stage a comeback in cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Mice carrying a CD20 gene disruption

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

CD20: a regulator of cell-cycle progression of B lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Signaling through sphingolipid microdomains of the plasma membrane: the concept of signaling platform

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Rituximab: perspective on single agent experience, and future directions in combination trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Signaling antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

The association between CD20 and Src-family Tyrosine kinases requires an additional factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Levels of expression of CD19 and CD20 in chronic B cell leukaemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Emerging information on the use of rituximab in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Rituximab: enhancing stem cell transplantation in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

In vivo purging and relapse prevention following ASCT.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Clinical trials of antibody therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402639

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402639

1 reference

Dimensions Publication ID

5 August 2017

1043080726

0 references

1 reference